E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Iron deficiency anaemia secondary to cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10002062 |
E.1.2 | Term | Anaemia iron deficiency |
E.1.2 | System Organ Class | 100000004851 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the feasibility of the current study design and aid design of a larger, definitive study. Feasibility will be assessed according to the following criteria 1. Eligible patients from screening 2. Study exclusion 3. Acceptability of recruitment 4. Study retention |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives will be as follows
1. To explore whether the use of intravenous iron affects the quality of life of anaemic patients undergoing palliation when compared to placebo.
2. To compare the haemoglobin responses between therapies.
3. To compare changes in blood iron storage (haematinics) between the two groups.
4. To compare differences in red blood cell transfusion rates between groups
5. To compare patient activity levels using a pedometer
6. To assess the tolerability of intravenous iron isomaltoside 1000 in this patient group.
7. To collect blood and faecal samples to investigate the effect of intravenous iron therapy on a) iron regulation in the body b) its effect on the immune system c) blood markers for tumour spread (tumour metastasis markers) d) gut bacteria in response to intravenous iron
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age ≥18 years 2. Histologically proven solid tumour 3. Haemoglobin < 130g/L men and <120 g/L women 4. ECOG (Eastern Cooperative Oncology Group, Oken 1982) performance status 0-2 5. Moderate to severe fatigue (numeric rating scale score ≥ 4 out of 10) 6. Cancer not amenable to curative treatment
|
|
E.4 | Principal exclusion criteria |
1. Evidence of iron overload or disturbance of iron utilisation e.g. haemachromotosis 2. Previous allergy to iron or related iron products 3. Evidence of active bleeding or untreated infection 4. Concurrent anti-cancer chemotherapy and/or immunotherapy and/or radiotherapy (within 8 weeks) 5. Untreated haematological malignancy 6. Female participants who are pregnant, lactating or planning a pregnancy during the course of the study. 7. Patients who are unable to consent 8. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study. 9. Thromboembolic event within 3 months unless on-going treatment with anticoagulation |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To determine the feasibility of the current study design and aid design of a larger, definitive study. Assessment of feasibility of study design will include 1. Eligible patients from screening 2. Study exclusion 3. Acceptability of recruitment 4. Study retention |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Feasibility measures will be assessed throughout the trial period from recruitment to follow up of patients over the 8 weeks following infusion. |
|
E.5.2 | Secondary end point(s) |
1. Quality of life scores as governed by the EQ-5D-5L, EORTC QLQc30 and FACIT-F questionnaires. 2. Change in the level of haemoglobin and haematinic markers following treatment with intravenous iron or placebo. 3. Allogenic blood transfusion number and volume. 4. To compare impact on exercise capacity and free living physical activity levels 5. Comparison of tolerability and adverse events in patients in both groups 6. Comparison of blood samples for hepcidin levels, cytokines and adhesion molecules between groups. Comparison of faecal samples for microbiome
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Questionnaires, exercise capacity, blood and stool samples will be evaluated at baseline and at the 4 and 8 week follow up visits. Pedometer activity will be evaluated for one week prior to baseline assessments and follow up visits. Blood transfusion number and volume will be evaluated at the end of patient participation at 8 weeks. Tolerability and adverse events will be evaluated for the duration of the trial following infusion until the end of follow up at 8 weeks.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Feasibility study to aid design of definitive trial. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |